ANIP News and Press, ANI Pharmaceuticals Inc. From 01/09/20

BAUDETTE, Minn. , Jan. 9, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share p...

BAUDETTE, Minn. , Dec. 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL.  Bretylium Tosylate is a class III antiarrhythmic medication approved for the treatment of ventricular fibri...

BAUDETTE, Minn. , Nov. 26, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston , Massachusetts. Arthur Przybyl, President and CEO, Robert Schrepfer , Senior Vice President Business...

ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 Non-GAAP EPS of $1.23 misses by $0.20 ; GAAP EPS of $0.32 misses by $0.32 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BAUDETTE, Minn. , Nov. 6, 2019 /PRNewswire/ -- For the third quarter 2019: Net revenues of $51.3 million , an increase of 1% versus prior year   GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32 Adjusted non-GAAP EBITDA of $19.8 milli...

BAUDETTE, Minn. , Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml)...

BAUDETTE, Minn. , Oct. 30, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, November 6, 2019 , before the opening of the U.S. financial markets. The...

BAUDETTE, Minn. , Oct. 29, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization (CDMO), today announced the launch of its new CDMO brand, ANI Global Source.  This ...

BAUDETTE, Minn. , Oct. 3, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the receipt of clinical data on Cortrophin® Gel (80 units/mL) from a study that evaluated the blood-level cortisol response in a 20-person healthy volunteer popul...

BAUDETTE, Minn. , Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®).  This launch represents ANI's fifth generic product...